REFERENCES

[1] Stefani M, Rigacci S. Protein folding and aggregation into amyloid: the interference by natural phenolic compounds. Int J Mol Sci 2013;14(6):12411-57.

[2] Herczenik E, Gebbink MFBG. Molecular and cellular aspects of protein misfolding and disease. FASEB J 2008;22(7):2115-33.

[3] Brahma A, Mandal C, Bhattacharyya D. Characterization of a dimeric unfolding intermediate of bovine serum albumin under mildly acidic condition. Biochim Biophys Acta,Proteins Proteomics 2005;1751(2):159-69.

[4] Militello V, Casarino C, Emanuele A, Giostra A, Pullara F, Leone M. Aggregation kinetics of bovine serum albumin studied by FTIR spectroscopy and light scattering. Biophys Chem 2004;107(2):175-87.

[5] Thai CK, Dai H, Sastry MSR, Sarikaya M, Schwartz DT, Baneyx F. Identification and characterization of Cu_2O- and ZnO-binding polypeptides by Escherichia coli cell surface display: toward an understanding of metal oxide binding. Biotechnol Bioeng 2004;87(2):129-37.

[6] Agorogiannis EI, Agorogiannis GI, Papadimitriou A, Hadjigeorgiou GM. Protein misfolding in neurodegenerative diseases. Neuropathol Appl Neurobiol 2004;30(3):215-24.

[7] Radford SE, Dobson CM. From computer simulations to human disease. Cell 2017;97(3):291-8.

[8] Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 2003;81(11):678-99.

[9] Fabrizio C, Christopher MD. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006;75(1):333-66.

[10] Dobson CM. Protein folding and misfolding. Nature 2003;426(6968):884-90.

[11] Selkoe DJ. Folding proteins in fatal ways. Nature 2003;426(6968):900-4.

[12] Serpell LC, Sunde M, Benson MD, Tennent GA, Pepys MB, Fraser PE. The protofilament substructure of amyloid fibrils. J Mol Biol 2000;300(5):1033-9.

[13] Nelson R, Eisenberg D. Recent atomic models of amyloid fibril structure. Curr Opin Struct Biol 2006;16(2):260-5.

[14] Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell 2012;148(6):1188-203.

[15] Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CCF. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 1997;273(3):729-39.

[16] Alam P, Siddiqi K, Chturvedi SK, Khan RH. Protein aggregation: from background to inhibition strategies. Int J Biol Macromol 2017;103:208-19.

[17] Lindberg DJ, Wenger A, Sundin E, Wesén E, Westerlund F, Esbjörner EK. Binding of Thioflavin-T to amyloid fibrils leads to fluorescence self-quenching and fibril compaction. Biochemistry 2017;56(16):2170-4.

[18] Wilson MR, Yerbury JJ, Poon S. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol Biosyst 2008;4(1):42-52.

[19] Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation:

implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993;32(18):4693-7.

[20] Peterson SA, Klabunde T, Lashuel HA, Purkey H, Sacchettini JC, Kelly JW. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci 1998;95(22):12956-60.

[21] van Gestel J, de Leeuw SW. The formation of fibrils by intertwining of filaments: model and application to amyloid Aβ protein. Biophys J 2007;92(4):1157-63.

[22] Hippius H, Neundörfer G. The discovery of Alzheimer's disease. Dialogues Clin Neurosci 2003;5(1):101-8.

[23] Alzheimer's A. 2017 Alzheimer's disease facts and figures2017. 325-73 p.

[24] Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer's disease. Nat Rev 2015;1:1-18.

[25] Holtzman DM, Bales KR, Paul SM, DeMattos RB. Aβ immunization and anti-Aβ antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Adv Drug Deliv Rev 2002;54(12):1603-13.

[26] Xia W, Zhang J, Kholodenko D, Citron M, Podlisny MB, Teplow DB, et al. Enhanced production and oligomerization of the 42-residue Amyloid β-protein by chinese hamster ovary cells stably expressing mutant presenilins J Biol Chem 1997;272(12):7977-82.

[27] Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain. J Clin Invest 2008;118(12):4002-13.

[28] Ries M, Sastre M. Mechanisms of Aβ clearance and degradation by glial cells. Front Aging Neurosci 2016;8:160.

[29] Yoon S-S, Jo SA. Mechanisms of Amyloid-β peptide clearance: potential therapeutic targets for Alzheimer's disease. Biomol Ther (Seoul) 2012;20(3):245-55.

[30] Götz J, Ittner A, Ittner LM. Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol 2012;165(5):1246-59.

[31] Hroudová J, Singh N, Fišar Z. Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer's disease. Biomed Res Int 2014;2014:1-9.

[32] Gu L, Guo Z. Alzheimer's $A\beta_{42}$ and $A\beta_{40}$ peptides form interlaced amyloid fibrils. J Neurochem 2013;126(3):305-11.

[33] Qiu T, Liu Q, Chen Y-X, Zhao Y-F, Li Y-MCPSCR. $A\beta_{42}$ and $A\beta_{40}$: similarities and differences. J Pept Sci 2015;21(7):522-9.

[34] Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Younkin LH, et al. Amyloid β protein (Aβ) in Alzheimeri's disease brain: biochemical and immunocytochemical analysis eith antibodies specific for forms ending at $A\beta_{40}$ or $A\beta_{42(43)}$. J Biol Chem 1995;270(13):7013-6.

[35] Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of $A\beta_{42(43)}$ and $A\beta_{40}$ in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is $A\beta_{42(43)}$. Neuron 2017;13(1):45-53.

[36] Teplow DB. Structural and kinetic features of amyloid β-protein fibrillogenesis. Amyloid 1998;5(2):121-42.

[37] Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006;440(7082):352-7.

[38] Murray PS, Kirkwood CM, Gray MC, Ikonomovic MD, Paljug WR, Abrahamson EE, et al. β-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis. Neurobiol Aging 2012;33(12):2807-16.

[39] Nutu M, Zetterberg H, Londos E, Minthon L, Nägga K, Blennow K, et al. Evaluation of the cerebrospinal fluid Amyloid-β1-42/Amyloid-β1-40 ratio measured by Alpha-LISA to distinguish Alzheimer's disease from other dementia disorders. Dement Geriatr Cogn Disord 2013;36(1-2):99-110.

[40] Peng X-L, Hou L, Xu S-H, Hua Y, Zhou S-J, Zhang Y, et al. Novel APP K724M mutation causes Chinese early-onset familial Alzheimer's disease and increases amyloid-β42 to amyloid-β40 ratio. Neurobiol Aging 2014;35(11):2657.e1-.e6.

[41] Fernandez MA, Klutkowski JA, Freret T, Wolfe MS. Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid β-peptides (Aβ)by γ-secretase to increase 42-to-40-residue Aβ. J Biol Chem 2014;289(45):31043-52.

[42] Wiltfang J, Esselmann H, Bibl M, Hüll M, Hampel H, Kessler H, et al. Amyloid β peptide ratio 42/40 but not $A\beta_{42}$ correlates with phospho-Tau in patients with low- and high-CSF $A\beta_{40}$ load. J Neurochem 2007;101(4):1053-9.

[43] Goure WF, Krafft GA, Jerecic J, Hefti F. Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. Alzheimers Res Ther 2014;6(4):42-.

[44] Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, et al. Structural conversion of neurotoxic amyloid-β1–42 oligomers to fibrils. Nat Struct Mol Biol 2010;17(5):561-7.

[45] Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, Acton P, et al. Solution state characterization of Amyloid β-derived diffusible ligands. Biochemistry 2006;45(51):15157-67.

[46] Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998;95(11):6448-53.

[47] Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of Amyloid β-protein begins intracellularly in cells derived from human brain. Biochemistry 2000;39(35):10831-9.

[48] Sengupta U, Nilson AN, Kayed R. The role of Amyloid-β oligomers in toxicity, propagation, and immunotherapy. EBioMedicine 2016;6:42-9.

[49] Garzon-Rodriguez W, Vega A, Sepulveda-Becerra M, Milton S, Johnson DA, Yatsimirsky AK, et al. A conformation change in the carboxyl terminus of Alzheimer's Aβ(1–40) accompanies the transition from dimer to fibril as revealed by fluorescence quenching analysis J Biol Chem 2000;275(30):22645-9.

[50] O'Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, et al. Aβ dimers rapidly form stable synaptotoxic protofibrils. J Neurosci 2010;30(43):14411-9.

[51] Kayed R, Lasagna-Reeves CA. Molecular mechanisms of amyloid oligomers toxicity J Alzheimers Dis 2012;33(s1):S67-S78.

[52] Morkuniene R, Cizas P, Jankeviciute S, Petrolis R, Arandarcikaite O, Krisciukaitis A, et al. Small Aβ1–42 oligomer-induced membrane depolarization of neuronal and microglial cells: role of N-methyl-D-aspartate receptors. J Neurosci Res 2015;93(3):475-86.

[53] Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, et al. Tramiprosate in mild-to-moderate Alzheimer's disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci 2011;7(1):102-11.

[54] Gupta-Bansal R, Frederickson RCA, Brunden KR. Proteoglycan-mediated inhibition of Aβ Proteolysis: a pothential cause of senile plaque accumulation. J Biol Chem 1995;270(31):18666-71.

[55] Janusz M, Zablocka A. Colostral Proline-rich polypeptides - immunoregulatory properties and prospects of therapeutic use in Alzheimer's disease. Curr Alzheimer Res 2010;7(4):323-33.

[56] Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011;77(13):1253-62.

[57] Matlack KES, Tardiff DF, Narayan P, Hamamichi S, Caldwell KA, Caldwell GA, et al. Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity. Proc Natl Acad Sci U S A 2014;111(11):4013-8.

[58] Robert A, Liu Y, Nguyen M, Meunier B. Regulation of copper and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimer's disease. Acc Chem Res 2015;48(5):1332-9.

[59] Ryan TM, Roberts BR, McColl G, Hare DJ, Doble PA, Li Q-X, et al. Stabilization of nontoxic Aβ-oligomers: insights into the mechanism of action of Hydroxyquinolines in Alzheimer's disease. J Neurosci 2015;35(7):2871-84.

[60] Wang Z, Wang Y, Li W, Mao F, Sun Y, Huang L, et al. Design, synthesis, and evaluation of multitarget-directed Selenium-containing Clioquinol derivatives for the treatment of Alzheimer's disease. ACS Chem Neurosci 2014;5(10):952-62.

[61] Pérez-Hernández J, Zaldívar-Machorro VJ, Villanueva-Porras D, Vega-Ávila E, Chavarría A. A potential alternative against neurodegenerative diseases: phytodrugs. Oxid Med Cell Longev 2016;2016:1-19.

[62] Ng YP, Or TCT, Ip NY. Plant alkaloids as drug leads for Alzheimer's disease. Neurochem Int 2015;89:260-70.

[63] Konrath EL, Passos CdS, Klein-Júnior LC, Henriques AT. Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer's disease. J Pharm Pharmacol 2013;65(12):1701-25.

[64] Matharu B, Gibson G, Parsons R, Huckerby TN, Moore SA, Cooper LJ, et al. Galantamine inhibits beta-amyloid aggregation and cytotoxicity. J Neurol Sci 2009;280(1):49-58.

[65] Melo JB, Sousa C, Garção P, Oliveira CR, Agostinho P. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons. Eur J Neurosci 2009;29(3):455-64.

[66] Asai M, Iwata N, Yoshikawa A, Aizaki Y, Ishiura S, Saido TC, et al. Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Aβ secretion. Biochem Biophys Res Commun 2007;352(2):498-502.

[67] Durairajan SSK, Huang Y-Y, Yuen P-Y, Chen L-L, Kwok K-Y, Liu L-F, et al. Effects of Huanglian-Jie-Du-Tang and its modified formula on the modulation of Amyloid-β precursor protein processing in Alzheimer's disease models. PLoS One 2014;9(3):e92954.

[68] Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, et al. Caffeine reverses cognitive impairment and decreases brain Amyloid-β levels in aged Alzheimer's disease mice J Alzheimers Dis 2009;17(3):661-80.

[69] Ngoungoure VLN, Schluesener J, Moundipa PF, Schluesener H. Natural polyphenols binding to amyloid: a broad class of compounds to treat different human amyloid diseases. Mol Nutr Food Res 2015;59(1):8-20.

[70] Sgarbossa A. Natural biomolecules and protein aggregation: emerging strategies against amyloidogenesis. Int J Mol Sci 2012;13(12):17121-37.

[71] Lee SJC, Nam E, Lee HJ, Savelieff MG, Lim MH. Towards an understanding of amyloid-β oligomers: characterization, toxicity mechanisms, and inhibitors Chem Soc Rev 2017;46(2):310-23.

[72] Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. Cummings, a potential role of the curry spice curcumin in Alzheimer's disease,. Curr Alzheimer Res 2005;2(2):131-6.

[73] Singh PK, Kotia V, Ghosh D, Mohite GM, Kumar A, Maji SK. Curcumin modulates alpha-synuclein aggregation and toxicity. ACS Chem Neurosci 2013;4(3):393-407.

[74] Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 2008;15(6):558-66.

[75] Feng Y, Wang X-p, Yang S-g, Wang Y-j, Zhang X, Du X-t, et al. Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology 2009;30(6):986-95.

[76] Jang J-H, Surh Y-J. Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med 2003;34(8):1100-10.

[77] Ono K, Hasegawa K, Naiki H, Yamada M. Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's β-amyloid fibrils in vitro. Biochim Biophys Acta 2004;1690(3):193-202.

[78] Ono K, Condron MM, Ho L, Wang J, Zhao W, Pasinetti GM, et al. Effects of grape seed-derived polyphenols on Amyloid β-protein self-assembly and cytotoxicity. J Biol Chem 2008;283(47):32176-87.

[79] Gazova Z, Siposova K, Kurin E, Mučaji P, Nagy M. Amyloid aggregation of lysozyme: The synergy study of red wine polyphenols. Proteins 2013;81(6):994-1004.

[80] Li S, Leblanc RM. Aggregation of insulin at the interface. J Phys Chem B 2014;118(5):1181-8.

[81] Orci L, Ravazzola M, Amherdt M, Madsen O, Vassalli J-D, Perrelet A. Direct identification of prohormone conversion site in insulin-secreting cells. Cell 1985;42(2):671-81.

[82] Jørgensen AMM, Olsen HB, Balschmidt P, Led JJ. Solution structure of the superactive monomeric Des-[Phe(B25)] human insulin mutant: elucidation of the structural basis for the monomerization of Des-[Phe(B25)] insulin and the dimerization of native insulin. J Mol Biol 1996;257(3):684-99.

[83] Groenning M, Frokjaer S, Vestergaard B. Formation mechanism of insulin fibrils and structural aspects of the insulin fibrillation process. Curr Protein Pept Sci 2009;10(5):509-28.

[84] Kelly JW. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 1998;8(1):101-6.

[85] Pasternack RF, Gibbs EJ, Sibley S, Woodard L, Hutchinson P, Genereux J, et al. Formation kinetics of insulin-based amyloid gels and the effect of added metalloporphyrins. Biophys J 2006;90(3):1033-42.

[86] Hua Q-x, Weiss MA. Mechanism of Insulin Fibrillation: The structure of insulin under amyloidogenic conditions resembles a protein-folding intermediate. J Biol Chem 2004;279(20):21449-60.

[87] Sluzky V, Klibanov AM, Langer R. Mechanism of insulin aggregation and stabilization in agitated aqueous solutions. Biotechnol Bioeng 1992;40(8):895-903.

[88] Bekard IB, Dunstan DE. Tyrosine autofluorescence as a measure of bovine Insulin fibrillation. Biophys J 2009;97(9):2521-31.

[89] Biancalana M, Koide S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta 2010;1804(7):1405-12.

[90] Voropai ES, Samtsov MP, Kaplevskii KN, Maskevich AA, Stepuro VI, Povarova OI, et al. Spectral properties of Thioflavin T and its complexes with amyloid fibrils. J Appl Spectrosc 2003;70(6):868-74.

[91] Stsiapura VI, Maskevich AA, Kuzmitsky VA, Turoverov KK, Kuznetsova IM. Computational study of Thioflavin T Torsional relaxation in the excited state. J Phys Chem A 2007;111(22):4829-35.

[92] Dzwolak W, Pecul M. Chiral bias of amyloid fibrils revealed by the twisted conformation of Thioflavin T: an induced circular dichroism/DFT study. FEBS Lett 2005;579(29):6601-3.

[93] Sen P, Fatima S, Ahmad B, Khan RH. Interactions of Thioflavin T with serum albumins: spectroscopic analyses. Spectrochim Acta A Mol Biomol Spectrosc 2009;74(1):94-9.

[94] Groenning M, Norrman M, Flink JM, van de Weert M, Bukrinsky JT, Schluckebier G, et al. Binding mode of Thioflavin T in insulin amyloid fibrils. J Struct Biol 2007;159(3):483-97.

[95] Khurana R, Ionescu-Zanetti C, Pope M, Li J, Nielson L, Ramírez-Alvarado M, et al. A general model for amyloid fibril assembly based on morphological studies using atomic force microscopy. Biophys J 2003;85(2):1135-44.

[96] Selkoe DJ. Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004;6:1054.

[97] Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300(5618):486-9.

[98] Manno M, Craparo EF, Podestà A, Bulone D, Carrotta R, Martorana V, et al. Kinetics of Different Processes in Human Insulin Amyloid Formation. J Mol Biol 2007;366(1):258-74.

[99] Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, et al. Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the $A\beta_{42}$ to $A\beta_{40}$ ratio. EMBO J 2010;29(19):3408-20.

[100] Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006;67(1):27-37.

[101] Pauwels K, Williams TL, Morris KL, Jonckheere W, Vandersteen A, Kelly G, et al. Structural basis for increased toxicity of pathological Aβ(42):Aβ(40) ratios in Alzheimer disease. J Biol Chem 2012;287(8):5650-60.